No Data
No Data
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
Smart Money Is Betting Big In NVO Options
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
FDA Warns Of Overdose Risks With Compounded Wegovy, Ozempic Injections
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Novo Nordisk's diabetes drug Victoza presented a "mixed" result in Alzheimer's disease research.
According to the statement released by the Alzheimer's Association, although Victoza did not show superiority to the placebo in improving glucose metabolism in the brains of Alzheimer's patients, it demonstrated potential benefits in slowing down cognitive decline and brain volume loss. Specifically, patients who took Victoza for one year exhibited an 18% slower rate of cognitive decline compared to those who took the placebo, and there was also a reduction in brain volume loss, which is of great significance for the treatment of Alzheimer's disease.
Mon Thu : Bank king I account RHB
Supermengg :![+1 👍](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f44d.png)
104804582 Mon Thu : https://www.moomoo.com/community/feed/112852755415045?share_code=01aXJl